Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
How can I offer my psoriasis patients the chance to look, move and feel better?
Psoriasis is caused by systemic inflammation, with manifestations that can affect more than just skin. These manifestations can have a dramatic impact on the way patients live their lives1,2. Explore the data below to understand how Cosentyx has shown fast and long-term relief.
CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA psoriatic arthritis; PsO, plaque psoriasis.